EAG Laboratories CEO Joins NuVasive Board

NuVasive Inc. is gaining a board member with more than two decades of medtech industry experience. 

Siddhartha Kadia, Ph.D., has been appointed to the company’s Board of Directors, effective Feb. 1.

“Siddhartha’s extensive leadership experience in bringing innovation to market and driving growth across global regions is well suited to support our purpose to transform surgery, advance care, and change lives,” said J. Christopher Barry, CEO of NuVasive. “This expertise, coupled with his knowledge of leading successful medical technology organizations, makes Siddhartha a great addition to our Board of Directors.”
 
Dr. Kadia has more than 20 years of experience in the medical technology industry with expertise in globally commercializing disruptive technology. He most recently served as president and CEO of EAG Laboratories, a global scientific services company providing analytical testing and consulting solutions, which was acquired by Eurofins Scientific for $780 million in December 2017.
 
“I’m passionate about improving our healthcare system and bringing technology to market that will help improve clinical, operational, and financial outcomes for surgeons, providers, and most importantly—for patients,” said Dr. Kadia. “I look forward to helping NuVasive deliver on its long-term strategy and value to its shareholders.”
 
Prior to EAG Laboratories, Dr. Kadia spent nine years with Life Technologies Corporation and its predecessor Invitrogen Corporation. Dr. Kadia held various positions with increasing responsibilities, including marketing and operations roles, as well as leadership roles in Japan and China. Most notably, he served as President, Life Sciences Division at Life Technologies where he managed a $2 billion product portfolio. Prior to Life Technologies, Dr. Kadia was a management consultant at McKinsey & Company in the Healthcare Practice, assisting global medical device companies, local and state governments, and healthcare providers.
 
Dr. Kadia earned a B.E. in electronics and telecommunications from Gujarat University in India, an M.S. in biomedical engineering from Rutgers University, and a Ph.D. in biomedical engineering from Johns Hopkins University. He is currently a board member of ALS Limited and BioSkryb. Dr. Kadia’s board experience also includes prior public company board service as a director of Volcano Corporation, Newport Corporation, and Horizon Discovery Group plc.